BRPI0406737A - Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus - Google Patents

Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus

Info

Publication number
BRPI0406737A
BRPI0406737A BR0406737-1A BRPI0406737A BRPI0406737A BR PI0406737 A BRPI0406737 A BR PI0406737A BR PI0406737 A BRPI0406737 A BR PI0406737A BR PI0406737 A BRPI0406737 A BR PI0406737A
Authority
BR
Brazil
Prior art keywords
peptide
systemic lupus
treatment
composition
lupus erythematosis
Prior art date
Application number
BR0406737-1A
Other languages
English (en)
Inventor
Sharon Cohen-Vered
Esmira Naftali
Vera Weinstein
Adrian Gilbert
Ety Klinger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0406737A publication Critical patent/BRPI0406737A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"FORMULAçõES PARENTERAIS DE UM PEPTìDEO PARA O TRATAMENTO DE ERITOMATOSE SISTêMICA DE LUPUS". A presente invenção prove uma composição farmacêutica compreendendo um veículo aquoso; de 0,1 mg/ml a 20 mg/ml da composição de um sal farmaceuticamente aceitável de um peptídeo possuindo a fórmula estrutural NH~ 2~-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH; e uma 13-ciclodextrina substituída em uma quantidade efetiva para dissolver o peptídeo no veículo aquoso, onde a composição possui um pH entre 4 e 9, um processo para preparação, e um método de aliviar sintomas de eritomatose sistêmica de lupus (SLE) em um indivíduo humano compreendendo administrar ao indivíduo humano a composição farmacêutica.
BR0406737-1A 2003-01-14 2004-01-14 Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus BRPI0406737A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43995003P 2003-01-14 2003-01-14
PCT/US2004/000955 WO2004064788A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
BRPI0406737A true BRPI0406737A (pt) 2005-12-20

Family

ID=32771763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406737-1A BRPI0406737A (pt) 2003-01-14 2004-01-14 Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus

Country Status (18)

Country Link
US (2) US7294687B2 (pt)
EP (1) EP1587525A4 (pt)
JP (1) JP2006516034A (pt)
KR (1) KR20050100616A (pt)
CN (1) CN1761477A (pt)
AU (1) AU2004206844A1 (pt)
BR (1) BRPI0406737A (pt)
CA (1) CA2513331A1 (pt)
CO (1) CO5640149A2 (pt)
CR (1) CR7936A (pt)
EA (1) EA008438B1 (pt)
EC (1) ECSP055960A (pt)
MX (1) MXPA05007552A (pt)
NO (1) NO20053761L (pt)
NZ (1) NZ541659A (pt)
UA (1) UA83816C2 (pt)
WO (1) WO2004064788A2 (pt)
ZA (1) ZA200506205B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
CA2513331A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries Ltd Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
DE102004043750A1 (de) * 2004-09-10 2006-03-30 Sanofi-Aventis Deutschland Gmbh Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
EP2124883A2 (en) * 2006-12-12 2009-12-02 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations and methods for making the same
EP2121139B1 (en) * 2007-01-16 2012-10-10 BiPar Sciences, Inc. Formulations for cancer treatment
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
PL3702374T3 (pl) 2012-02-15 2022-11-21 Cydex Pharmaceuticals, Inc. Sposób wytwarzania pochodnych cyklodekstryny
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
AU2018205885A1 (en) 2017-01-05 2019-06-27 Yeda Research And Development Co. Ltd. Peptides for treating Sjogren's syndrome
CN110960442B (zh) * 2019-12-17 2023-03-31 珠海冀百康生物科技有限公司 一种多肽包封物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
EP1045836B1 (en) 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7114005B2 (en) 2002-02-05 2006-09-26 Cisco Technology, Inc. Address hopping of packet-based communications
CA2513331A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries Ltd Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus

Also Published As

Publication number Publication date
WO2004064788A3 (en) 2005-03-24
NO20053761L (no) 2005-10-12
US20080287366A1 (en) 2008-11-20
EP1587525A4 (en) 2008-09-10
EA008438B1 (ru) 2007-06-29
AU2004206844A1 (en) 2004-08-05
UA83816C2 (ru) 2008-08-26
CR7936A (es) 2006-05-31
EA200501129A1 (ru) 2006-02-24
US7294687B2 (en) 2007-11-13
US20040180059A1 (en) 2004-09-16
KR20050100616A (ko) 2005-10-19
CN1761477A (zh) 2006-04-19
ZA200506205B (en) 2006-12-27
NZ541659A (en) 2007-05-31
JP2006516034A (ja) 2006-06-15
MXPA05007552A (es) 2006-05-19
CA2513331A1 (en) 2004-08-05
CO5640149A2 (es) 2006-05-31
WO2004064788A2 (en) 2004-08-05
ECSP055960A (es) 2006-04-19
EP1587525A2 (en) 2005-10-26
NO20053761D0 (no) 2005-08-08

Similar Documents

Publication Publication Date Title
BRPI0406737A (pt) Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
US20110040072A1 (en) Mono and di-substituted oxycodone compounds and compositions
US20080090771A1 (en) Abuse-resistant hydrocodone compounds, compositions and methods of using the same
JP2009533459A (ja) 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
NZ546226A (en) Oxycodone conjugates for prevention of overdose or abuse
US20080207668A1 (en) Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
US2662046A (en) Parenteral amino acid solution
RU2005140680A (ru) Фармацевтическая композиция для фотодинамической терапии и способ лечения онкологического заболевания с ее использованием
AU2001280052B2 (en) Pharmaceutical composition comprising an analgesic peptide
CA3129636A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
US20110136742A1 (en) Antidepressant prodrugs
US20080234206A1 (en) Prodrugs of Phentermine
US20060189536A1 (en) Treating the effects of nicotine
WO2004058303A3 (en) Compositions of benzoquinolizine carboxylic acid antibiotic drugs
JP2641742B2 (ja) 新規ペプチド及び抗菌剤
KR102499473B1 (ko) 여성 성기능장애를 치료하기 위한 신규한 펩타이드군
ZA200608865B (en) Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives
JPH0262559B2 (pt)
JP2641744B2 (ja) 新規ペプチド及び抗菌剤
Brinkworth et al. Host defence peptides from the skin glands of Australian amphibians. Caerulein neuropeptides and antimicrobial, anticancer, and nNOS inhibiting citropins from the glandular frog Litoria subglandulosa
US20200237926A1 (en) pHLIP® targeted delivery of potent cytotoxic compounds
CN116392602A (zh) 两亲性多肽载体及其应用
KR20180046888A (ko) 안정한 약제학적 제제
JP2004300074A (ja) エルカトニン水溶液組成物

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.